Ultragenyx Pharmaceutical Inc. (RARE) reported that its second quarter net loss narrowed to $131.60 million or $1.52 per share from $159.83 million or $2.25 per share in the prior year.
Quarterly total revenues were $147.03 million, represents 36% growth compared to the same period in 2023.
Analysts polled by Thomson Reuters expected the company to report a loss of $1.69 per share and revenues of $123.18 million for the second quarter. Analysts' estimates typically exclude special items.
The company raised its fiscal year 2024 total revenue guidance to a range of $530 million to $550 million from the prior estimation of $500 million to $530 million. Analysts expected revenue of $513.16 million for fiscal year.
RARE closed Thursday's regular trading at $44.15 down $0.87 or 1.93%. But in the after-hours trading, the stock gained $3.82 or 8.65%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.